Compare Nokia Corp (NOK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs 10X Genomics Inc — how do they compare? Nokia Corp trades at $10.78 (market cap $59.77B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Nokia Corp is far larger — about 7× 10X Genomics Inc's market cap, and Nokia Corp pays a 1.53% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| NOK | TXG | |
|---|---|---|
Market Cap | $59.77B | $8.55B |
Sector | Technology | Health |
52-Week High | $16.83 | $67.29 |
52-Week Low | $4.51 | $11.34 |
Enterprise Value | $57.71B | $8.08B |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% on the day, supported by a bullish technical signal and positive momentum from AI-driven network infrastructure growth. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with revenue stabilizing around $20 billion annually. Analyst sentiment is predominantly bullish, with 61.5% recommending Buy, amid news of its return to the Euro Stoxx 50 index and expansion in Saudi AI research.
The outlook is cautiously optimistic, driven by AI and cloud demand, but risks include competitive pressures, volatile cash flow, and high valuation multiples. Investment opportunity hinges on execution of growth initiatives, while shareholders face exposure to telecom sector volatility and margin challenges.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
